Tryptoline-based benzothiazoles re-sensitize MRSA to β-lactam antibiotics
摘要:
Resistance-modifying agents (RMAs) offer a promising solution to combat bacterial antibiotic resistance. Here we report the discovery and structure-activity relationships of a new class of RMAs with a novel tryptoline-based benzothiazole scaffold. Our most potent compound in this series (4ad) re-sensitizes multiple MRSA strains to cephalosporins at low concentrations (2 mu g/mL) and has low mammalian cytotoxicity with a half growth inhibitory concentration (GI(50)) > 100 mu g/mL in human cervical carcinoma (HeLa) cells. In addition, the same core scaffold with different substitutions also gives good antibacterial activity against MRSA.
[EN] TRYPTOLINE-BASED BENZOTHIAZOLES AND THEIR USE AS ANTIBIOTICS AND ANTIBIOTIC RESISTANCE-MODIFYING AGENTS<br/>[FR] BENZOTHIAZOLES À BASE DE TRYPTOLINE ET LEUR UTILISATION EN TANT QU'ANTIBIOTIQUES ET AGENTS MODIFIANT LA RÉSISTANCE AUX ANTIBIOTIQUES
申请人:UNIV COLORADO REGENTS
公开号:WO2021046194A1
公开(公告)日:2021-03-11
The present inventions relates to tryptoline-based benzothi azole compounds and their use as both novel resistance modifying agents, and antibiotics.
本发明涉及基于色胺的苯并噻唑类化合物及其用作新型耐药修饰剂和抗生素的用途。
DOU H. J. M.; HASSANALY P.; KISTER J.; VERNIN G.; METZGER J., HELV. CHIM. ACTA, 1978, 61, NO 8, 3143-3148
作者:DOU H. J. M.、 HASSANALY P.、 KISTER J.、 VERNIN G.、 METZGER J.
DOI:——
日期:——
Propionsäureester und deren Verwendung als Unkrautbekämpfungsmittel
申请人:F. HOFFMANN-LA ROCHE & CO.
Aktiengesellschaft
公开号:EP0121871B1
公开(公告)日:1988-01-20
Tryptoline-Based Benzothiazoles and their use as Antibiotics and Antibiotic Resistance-Modifying Agents
申请人:The Regents of the University of Colorado, a body corporate
公开号:US20220402914A1
公开(公告)日:2022-12-22
The present inventions relates to tryptoline-based benzothiazole compounds and their use as both novel resistance modifying agents, and antibiotics.
Tryptoline-based benzothiazoles re-sensitize MRSA to β-lactam antibiotics
作者:Xinfeng Wang、Jinsen Chen、Wei Wang、Anna Jaunarajs、Xiang Wang
DOI:10.1016/j.bmc.2019.115095
日期:2019.11
Resistance-modifying agents (RMAs) offer a promising solution to combat bacterial antibiotic resistance. Here we report the discovery and structure-activity relationships of a new class of RMAs with a novel tryptoline-based benzothiazole scaffold. Our most potent compound in this series (4ad) re-sensitizes multiple MRSA strains to cephalosporins at low concentrations (2 mu g/mL) and has low mammalian cytotoxicity with a half growth inhibitory concentration (GI(50)) > 100 mu g/mL in human cervical carcinoma (HeLa) cells. In addition, the same core scaffold with different substitutions also gives good antibacterial activity against MRSA.